Key result
Current therapies for Chagas disease, benznidazole and nifurtimox, are decades old, highly toxic, and have disputed efficacy in the chronic phase, highlighting the urgent need for new drug discovery.
Population
Patients with Chagas disease (Trypanosoma cruzi infection)
Design
Review
Authors
Loading...
Existing Chagas options warrant toxicity caution in chronic use; leaves open priority for novel safer agents targeting cardiomyopathy.
This review emphasizes the critical need for new, safer, and more effective anti-parasitic treatments for Chagas disease to prevent and manage its debilitating chronic complications, such as cardiomyopathy.
Gaspar et al. (2015) conducted a review in Chagas disease. Chemotherapy (Benznidazole, Nifurtimox) was evaluated. Current therapies for Chagas disease, benznidazole and nifurtimox, are decades old, highly toxic, and have disputed efficacy in the chronic phase, highlighting the urgent need for new drug discovery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: